[99mTc]sestamibi and [99mTc]tetrofosmin in oncology: SPET and fusion imaging in lung cancer, malignant lymphomas and brain tumors

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 49, Issue 2, 2005, Pages 133-144

  Schillaci, O ^a   Spanu, A ^b   Madeddu, G ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

99mTc cationic complexes; Brain neoplasms; Computed tomography; Lung neoplasms; Lymphoma; Single photon emission computed tomography

Indexed keywords

DIAGNOSTIC AGENT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,2 BIS(BIS(2 ETHOXYETHYL)PHOSPHINO)ETHANE; TECHNETIUM TC 99M 1,2-BIS(BIS(2-ETHOXYETHYL)PHOSPHINO)ETHANE;

BRAIN TUMOR; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMAGE SUBTRACTION; LUNG TUMOR; LYMPHOMA; METHODOLOGY; ONCOLOGY; RADIOGRAPHY; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN NEOPLASMS; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MEDICAL ONCOLOGY; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; SUBTRACTION TECHNIQUE; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33748142147     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Schomacker K, Schicha H. Use of myocardial imaging agents for tumour diagnosis - a success story? Eur J Nucl Med 2000;27:1845-63.
2. Schillaci O, Danieli R, Manni C, Capoccetti F, Simonetti G. The added clinical value of SPET/CT with a hybrid imaging system. J Nucl Med 2003;44:290P.
3. Maublant J, Zhang Z, Rapp M, Ollier M, Michelot J, Veyre A. In vitro uptake of technetium-99m-teboroxime in carcinoma cell lines and normal cells: comparison with technetium-99m-sestamibi and thallium-201. J Nucl Med 1993;34:1949-52.
4. Scopinaro F, Schillaci O, Scarpini M, Minagazzini PL, Di Macio L, Banci M, et al. Technetium-99m-sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med 1994;21:984-7.
5. Arbab AS, Koizumi K, Toyama K, Araki T. Uptake of technetium-99m- tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines. J Nucl Med 1996;37:1551-6.
6. Hendrikse NH, Franssen EJ, van der Graaf WT, Vaalburg W, de Vries EG. Visualization of multidrug resistance in vivo. Eur J Nucl Med 1999;26:283-93.
7. Perek N, Denoyer D. The multidrug resistance mechanisms and their interactions with the radiopharmaceutical probes used for an in vivo detection. Curr Drug Metab 2002;3:97-113.
8. Maisey MN, Hawkes DJ, Lukswiecki-Vydelingum AM. Synergistic imaging. Eur J Nucl Med 1992;19:1002-5.
9. von Schulthess GK, Pelc NJ. Integrated-modality imaging: the best of both worlds. Acad Radiol 2002;9:1241-4.
10. Schillaci O, Simonetti G. Fusion imaging in nuclear medicine-applications of dual-modality systems in oncology. Cancer Biother Radiopharm 2004;19:1-10. (Pubitemid 38352280)
11. Schillaci O, Danieli R, Picardi V, Manni C, Capocetti F, Pasquarelli R et al. A combined SPET/CT imaging system for functional anatomical mapping: initial clinical applications. Eur J Nucl Med Mol Imaging 2002;29 (Suppl 1):S94.
12. Schillaci O, Danieli R, Manni C, Simonetti G. Is SPET/CT with a hybrid camera useful to improve scintigraphic imaging interpretation? Nucl Med Commun 2004;25:705-10. (Pubitemid 38901688)
13. Nosotti M, Santambrogio L, Gasparini M, Baisi A, Bellaviti N, Rosso L. Role of 99mtc-hexakis-2-methoxy-isobutylisonitrile in the diagnosis and staging of lung cancer. Chest 2002;122:1361-4. (Pubitemid 35339553)
14. Kao CH, Wang SJ, Lin WJ, Hsu CY, Liao SQ, Yeh SH. Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m mathoxy-isobutylisonitrile. Eur J Nucl Med 1993;20:249-54.
15. Kao CH, ChangLai SH, Shen YY, Lee KJ, Wang SJ. Technetium-99m-tetrofosmin SPET imaging of lung masses: a negative study. J Nucl Med 1997;38:1015-9.
16. Schillaci O, Monteleone F, D'Andrea N, Picardi V, Cangemi R, Cangemi V, et al. Technetium-99m tetrofosmin single photon emission computed tomography in the evaluation of suspected lung cancer. Cancer Biother Radiopharm 1999;14:129-34.
17. 99mTc-tetrofosmin scintigraphy in lung carcinoma staging and follow-up evaluations. Cancer 2002;94:1796-807.
18. 99mTc-tetrofosmin SPET in the detection of intrathoracic malignant lesions. Int J Oncol 2003;22:639-49.
19. 99mTc-tetrofosmin SPET in solitary pulmonary nodule evaluation. J Nucl Med 2004;45:376P.
20. Ost D, Fein AM, Feinsilver SH. Clinical practice. The solitary pulmonary nodule. N Engl J Med 2003;348:2535-42.
21. Minai OA, Raja S, Mehta AC, Sullivan EJ, Khan SU, Dasgupta A, et al. Role of Tc-99m MIBI in the evaluation of single pulmonary nodules: a preliminary report. Thorax 2000;55:60-2.
22. Yap CS, Schiepers C, Fishbein MC, Phelps ME, Czernin J. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? Eur J Nucl Med Mol Imaging 2002;29:1166-73.
23. Higuchi T, Tagawa S, Yoshida N, Araki T, Tsuchiya T, Higashi K, et al. Discrepant uptake between fluorine-18 fluorodeoxy glucose and Tc-99m-sestamibi in bronchioloalveolar cell carcinoma. Ann Nucl Med 2003;17:499-501.
24. Mountain CF. The international system for staging lung cancer. Semin Surg Oncol 2000;18:106-15.
25. Friedman PJ. Lung cancer staging: efficacy of CT. Radiology 1992;182:307-9.
26. Chiti A, Maffioli LS, Infante M, Grasselli G, Carbone M, Gasparini M, et al. Assessment of mediastinal involvement in lung cancer with technetium-99m-sestamibi SPET. J Nucl Med 1996;37:938-42.
27. 99mTc-tetrofosmin SPET and comparison with CT. J Nucl Med 2003;44:1219-24.
28. Shiun SC, Sun SS, Hsu NY, Kao CH, Lin CC, Lee CC. Detecting mediastinal lymph node metastases in non-small-cell lung cancer using a combination of technetium-99m tetrofosmin chest single photon emission computed tomography and chest computed tomography. Cancer Invest 2002;20:311-7.
29. 99mTc-MIBI SPET. Eur J Nucl Med 2001;28:799-806.
30. Spanu A, Ginesu F, Pirina P, Schillaci O, Farris A, Chessa F, et al. The usefulness of 99mTc-tetrofosmin SPET in monitoring the response to chemotherapy in lung cancer patients. Oncol Rep 2003;10:1701-7.
31. Kostakoglu L, Elahi N, Kiratli P, Ruacan S, Sayek I, Baltali E, et al. Clinical validation of the influence of P-glycoprotein on technetium-99m- sestamibi uptake in malignant tumors. J Nucl Med 1997;38:1003-8.
32. Kostakoglu L, Kiratli P, Ruacan S, Hayran M, Emri S, Ergun EL, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med 1998;39:228-34.
33. Zhou J, Higashi K, Ueda Y, Kodama Y, Guo D, Jisaki F, et al. Expression of multidrug resistance protein and messenger RNA correlate with (99m)Tc-MIBI imaging in patients with lung cancer. J Nucl Med 2001;42:1476-83.
34. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis. Eur J Nucl Med Mol Imaging 2002;29:876-81.
35. Yeh JJ, Hsu WH, Huang WT, Wang JJ, Ho ST, Kao A. Technetium-99m tetrofosmin SPET predicts chemotherapy response in small cell lung cancer. Tumour Biol 2003;24:151-5.
36. 99mTc-tetrofosmin chest imaging. J Nucl Med. 2001;42:17-20.
37. 67Ga scanning in the staging of malignant lymphoma. Success and failures. J Nucl Med 1972;13:474-5.
38. Iosilevsky G, Front D, Bettman L, Hardoff R, Ben-Arieh Y. Uptake of gallium-67 citrate and [2-3H]deoxyglucose in the tumor model following chemotherapy and radiotherapy. J Nucl Med 1985;26:278-82. (Pubitemid 16216541)
39. Kaplan W. Residual mass and negative gallium scintigraphy in treated lymphoma: When is gallium scan really negative (editorial). J Nucl Med 1990;3:369-71.
40. Kostakoglu L, Yeh SDJ, Portlock C, Heelan R, Yao TJ, Niedzwieki D, et al. Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med 1992;33:345-50.
41. Schuster DM, Alazraki N. Gallium and other agents in diseases of the lung. Semin Nucl Med 2002;32:193-211. (Pubitemid 34803592)
42. Even-Sapir E, Israel O. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. Eur J Nucl Med Mol Imaging 2003;30 (Suppl 1):S65-S81. (Pubitemid 36735764)
43. Ziegels P, Nocaudie M, Huglo D, Deveaux M, Detourmignies L, Wattel E, et al. Comparison of technetium-99m methoxyisobutylisonitrile and gallium-67 citrate scanning in the assessment of lymphomas. Eur J Nucl Med 1995;22:126-31.
44. Yang CC, Sun SS, Lin CC, Kao CH, Lee CC. Comparison of technetium-99m tetrofosmin and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Anticancer Res 2001;21:3695-8.
45. Maurea S, Acampa W, Varrella P, De Rosa V, Figiani P, Abate G, et al. Tc-99m-sestamibi imaging in the diagnostic assessment of patients with lymphomas: comparison with clinical and radiological evaluation. Clin Nucl Med 1998;23:283-90.
46. 99Tcm-tetrofosmin scintigraphy in Hodgkin's disease. Nucl Med Commun 1997;18:252-7.
47. Schillaci O, Filippis AM, Anselmo AP, Monteleone F, Capoccetti F, Massa R, et al. Technetium-99m tetrofosmin imaging in malignant lymphomas. Tumori 2002;88:S24-25.
48. 99Tc(m)-sestamibi SPET brain imaging for differentiating intracranial lymphoma from non-malignant lesions in AIDS patients. Nucl Med Commun 1998;19:47-53.
49. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, Lorenz WJ, Maier-Borst W, van Kaick G. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995;22:434-42.
50. Kapucu LO, Akyuz C, Vural G, Oguz A, Atasever T, Buyukpamukcu M, et al. Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi. J Nucl Med 1997;38:243-7.
51. Liang JA, Shiau YC, Yang SN, Lin FJ, Lin CC, Kao A, et al. Using technetium-99m-tetrofosmin scan to predict chemotherapy response of malignant lymphomas, compared with P-glycoprotein and multidrug resistance related protein expression. Oncol Rep 2002;9:307-12.
52. Kao CH, Tsai SC, Wang JJ, Ho YJ, Ho ST, Changlai SP. Evaluation of chemotherapy response using technetium-99M-sestamibi scintigraphy in untreated adult malignant lymphomas and comparison with other prognosis factors: a preliminary report. Int J Cancer 2001;95:228-31.
53. Ohta M, Isobe K, Kuyama J, Uchida Y, Nakano K, Goto S, et al. Clinical role of Tc-99m-MIBI scintigraphy in non-Hodgkin's lymphoma. Oncol Rep 2001;8:841-5.
54. Del Sole A, Moncayo R, Tafuni G, Lucignani G. Position of nuclear medicine techniques in the diagnostic work-up of brain tumors. Q J Nucl Med Mol Imaging 2004;48:76-81.
55. Baillet G, Albuquerque L, Chen Q, Poisson M, Delattre JY. Evaluation of single-photon emission tomography imaging of supratentorial brain gliomas with technetium-99m sestamibi. Eur J Nucl Med 1994;21:1061-6.
56. 99Tcm-sestamibi. Nucl Med Commun 1995;16:258-64.
57. Soricelli A, Cuocolo A, Varrone A, Discepolo A, Tedeschi E, Mainenti PP, et al. Technetium-99m-tetrofosmin uptake in brain tumors by SPET: comparison with thallium-201 imaging. J Nucl Med 1998;5:802-6.
58. 18F-fluorodeoxyglucose. J Neurooncol 2000;46:63-70.
59. Minutoli F, Angileri FF, Cosentino S, Pecorella GR, Cardali S, De Divitiis O, et al. 99mTc-MIBI SPET in distinguishing neoplastic from nonneoplastic intracerebral hematoma. J Nucl Med 2003;44:1566-73.
60. Filippi L, Santoni R, Manni C, Danieli R, Floris R, Schillaci O. Imaging primary brain tumors by single-photon emission computerized tomography with technetium-99m-sestamibi and tetrofosmin. Curr Med Imaging Rev 2005;1:61-6.
61. Barai S, Bandopadhayaya GP, Julka PK, Haloi AK, Seith A, Malhotra A. Evaluation of single photon emission computerised tomography (SPED using Tc99m-tetrofosmin as a diagnostic modality for recurrent posterior fossa tumours. J Postgrad Med 2003;49:316-21.
62. Maffioli L, Gasparini M, Chiti A, Gramaglia A, Mongioj V, Pozzi A et al. Clinical role of technetium-99m-sestamibi single-photon emission tomography in evaluating pretreated patients with brain tumours. Eur J Nucl Med 1996;23:308-11.
63. Soler C, Beauchesne P, Maatougui K, Schmitt T, Barral FG, Michel D et al. Technetium-99m-sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy. Eur J Nucl Med 1998;25:1649-57.
64. 99mTc-sestamibi brain SPET after chemoradiotherapy is prognostic of survival in patients with high-grade glioma. J Nucl Med 2004;45:409-13.
65. Prigent-Le Jeune F, Dubois F, Perez S, Blond S, Steinling M. Technetium-99m-sestamibi brain SPET in the follow-up of glioma for evaluation of response to chemotherapy: first results. Eur J Nucl Med Mol Imaging 2004;31:714-9.
66. Yokogami K, Kawano H, Moriyama T, Uehara H, Sameshima T, Oku T et al. Apphcation of SPET using technetium-99m-sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET? Eur J Nucl Med 1998;25:401-9.
67. Shibata Y, Matsumura A, Nose T. Effect of expression of P-glycoprotein on technetium-99m methoxyisobutylisonitrile single photon emission computed tomography of brain tumours. Neurol Med Chir 2002;42:325-30.